stockrowPenumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
Follow PEN
Alert me
Penumbra, Inc. (PEN) Shares outstanding
Penumbra, Inc.'s shares outstanding at the end of fiscal 2025 was $39.3M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $39.6M. Over the past ten years it has ranged from $14.2M (fiscal 2015) to $39.3M (fiscal 2025) — the current reading is the highest in ten years. Penumbra, Inc. ranks 75th of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $39.3M | 0.06% |
| FY2024 | $39.3M | 0.13% |
| FY2023 | $39.2M | 3.63% |
| FY2022 | $37.8M | (0.10%) |
| FY2021 | $37.9M | 5.91% |
| FY2020 | $35.8M | (1.38%) |
| FY2019 | $36.3M | 0.50% |
| FY2018 | $36.1M | 2.17% |
| FY2017 | $35.3M | 5.50% |
| FY2016 | $33.5M | 135.43% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $39.6M | 0.12% |
| Jun 2026 | $39.6M | 0.07% |
| Mar 2026 | $39.5M | 0.64% |
| Dec 2025 | $39.3M | (0.03%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $449.4M |
| BRKR Bruker Corporation compare | $152.5M |
| GMED Globus Medical, Inc. compare | $136.0M |
| TXG 10x Genomics compare | $130.0M |
| PODD Insulet Corporation compare | $69.5M |
| GKOS Glaukos Corporation compare | $61.2M |
| PEN Penumbra, Inc. | $39.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $26.9M |
| BIO Bio-Rad Laboratories, Inc. compare | $26.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on PEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement